Richard Zhang

Richard Zhang

Auto-generated profile, based on publicly available information

Richard Zhang

McMaster University, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in International Journal of E-Health and Medical Communications
Verified
Journal Article
Open access
PDF file
CDCarol DeMatteo
Carol DeMatteo
JJJosephine Jakubowski
Josephine Jakubowski
KSKathy Stazyk
Kathy Stazyk
SRSarah Randall
Sarah Randall
SPSamantha Perrotta
Samantha Perrotta
RZRichard Zhang
Richard Zhang
This descriptive manuscript describes challenges, solutions, and recommendations to provide a supportive framework for clinician researchers striving to develop a clinical app. The Back2Play app aims to support youth in concussion recovery through mobile health monitoring. Developed in Phase 1 of a randomized control trial, the app intends to prevent re-injury and improve recovery by integrating evidence-based return-to-school and activity guidelines with biological monitoring. Methods outline the stages of successful app development. Identified challenges include defining app requirements, database hosting, development, and legal procedures. Results of usability testing show that the Back2Play app was highly acceptable to 66% of youth and none found it unacceptable. Successful clinical app development hinges on understanding the scope of the app, data management and exportation. Adequate funds should also be allocated for potential delays. These recommendations provide a framework for clinical researchers hoping to develop a clinical app that achieves their envisioned outcome.

23 December 2025 in bioRxiv
Verified
Preprint
Open access
RZRichard Zhang
Richard Zhang
ADAlan A. Díaz-Montiel
Alan A. Díaz-Montiel
NBNooshin Bahador
Nooshin Bahador
MLMilad Lankarany
Milad Lankarany
Epilepsy affects over 50 million individuals, many of whom require surgical treatment that is dependent on accurate localization of the seizure onset zone (SOZ). Conventional SOZ biomarkers are based on strictly defined intracranial electroen-cephalography (iEEG) phenomena and cannot benefit from increased datasets. The scarcity of SOZ-labeled iEEG data impedes biomarker development. We introduce the Data-driven Importance MEtric (DIME) to guide SOZ localization in an interpretable pipeline that improves with ictal-labeled iEEG data. We apply DIME to an open-source dataset (n=21; 13 successful; 8 failed) for SOZ localization and surgical outcome prediction. The highest DIME-ranked electrode belonged to the clinically annotated SOZ for 69.2% of patients with successful surgery ( p < 0.001 ). DIME scores were significantly higher in SOZ electrodes than nonSOZ electrodes in both successful and failed surgeries ( p < 0.001 ), though the DIME distribution for successful cases differed from failed cases ( p = 0.002 ). DIME predicted surgical outcome with 92.3% recall and 66.7% accuracy.